Luc J J Derijks

Summary

Affiliation: Maasland Hospital
Country: The Netherlands

Publications

  1. ncbi Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy
    Luc J J Derijks
    Department of Clinical Pharmacy, Maasland Hospital Sittard, St Laurentius Hospital, Roermond, The Netherlands
    Ther Drug Monit 26:311-8. 2004
  2. ncbi Pharmacokinetics of 6-thioguanine in patients with inflammatory bowel disease
    Luc J J Derijks
    Department of Clinical Pharmacy, Maxima Medical Center, Veldhoven, The Netherlands
    Ther Drug Monit 28:45-50. 2006
  3. ncbi Thiopurines in inflammatory bowel disease: new strategies for optimization of pharmacotherapy?
    Luc J J Derijks
    Department of Clinical Pharmacy, Maxima Medical Center, PO Box 7777, 5500 MB Veldhoven, The Netherlands
    Curr Gastroenterol Rep 8:89-92. 2006
  4. ncbi 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment
    Luc J J Derijks
    Department of Clinical Pharmacy, Maasland Hospital, Sittard, The Netherlands
    Eur J Gastroenterol Hepatol 15:63-7. 2003
  5. ncbi Pharmacogenetics of thiopurines in inflammatory bowel disease
    Luc J J Derijks
    Department of Clinical Pharmacy, Maxima Medical Centre, PO Box 7777, 5500 MB Veldhoven, The Netherlands
    Curr Pharm Des 16:145-54. 2010
  6. ncbi The role of xanthine oxidase in thiopurine metabolism: a case report
    Dennis R Wong
    Department of Clinical Pharmacy, Orbis Medical Center, Maasland Hospital, Sittard, The Netherlands
    Ther Drug Monit 29:845-8. 2007
  7. pmc Serotonin transporter polymorphism and bleeding time during SSRI therapy
    Dahlia M C Hougardy
    Department of Clinical Pharmacy, Maxima Medical Center, Veldhoven, The Netherlands
    Br J Clin Pharmacol 65:761-6. 2008
  8. ncbi Promising treatment of autoimmune hepatitis with 6-thioguanine after adverse events on azathioprine
    Nanne K H de Boer
    Dept of Gastroenterology and Hepatology, VU University Medical Center, Amsterdam, The Netherlands
    Eur J Gastroenterol Hepatol 17:457-61. 2005
  9. ncbi 6-Thioguanine-related hepatotoxicity in patients with inflammatory bowel disease: dose or level dependent?
    Luc J J Derijks
    J Hepatol 44:821-2. 2006
  10. ncbi Some cases demonstrating the clinical usefulness of therapeutic drug monitoring in thiopurine-treated inflammatory bowel disease patients
    Lennard P L Gilissen
    Department of Gastroenterology, Maasland Hospital, Sittard, The Netherlands
    Eur J Gastroenterol Hepatol 16:705-10. 2004

Collaborators

Detail Information

Publications12

  1. ncbi Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy
    Luc J J Derijks
    Department of Clinical Pharmacy, Maasland Hospital Sittard, St Laurentius Hospital, Roermond, The Netherlands
    Ther Drug Monit 26:311-8. 2004
    ..0 (CI95% 1.7-92.3) of developing leukopenia. A 6-MMPR/6-TGN ratio less than 11 was associated with therapeutic efficacy. Based on this pharmacokinetic analysis, therapeutic drug monitoring is essential for rational 6-MP dosing...
  2. ncbi Pharmacokinetics of 6-thioguanine in patients with inflammatory bowel disease
    Luc J J Derijks
    Department of Clinical Pharmacy, Maxima Medical Center, Veldhoven, The Netherlands
    Ther Drug Monit 28:45-50. 2006
    ..In our population, we could not demonstrate a clear relationship between 6-TGN concentrations on one hand and toxicity and efficacy on the other, as exist in AZA- and 6-MP-treated patients...
  3. ncbi Thiopurines in inflammatory bowel disease: new strategies for optimization of pharmacotherapy?
    Luc J J Derijks
    Department of Clinical Pharmacy, Maxima Medical Center, PO Box 7777, 5500 MB Veldhoven, The Netherlands
    Curr Gastroenterol Rep 8:89-92. 2006
  4. ncbi 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment
    Luc J J Derijks
    Department of Clinical Pharmacy, Maasland Hospital, Sittard, The Netherlands
    Eur J Gastroenterol Hepatol 15:63-7. 2003
    ..The purpose of our study was to assess the short-term safety of 6-TG...
  5. ncbi Pharmacogenetics of thiopurines in inflammatory bowel disease
    Luc J J Derijks
    Department of Clinical Pharmacy, Maxima Medical Centre, PO Box 7777, 5500 MB Veldhoven, The Netherlands
    Curr Pharm Des 16:145-54. 2010
    ..Pharmacogenetic knowledge in this field has increased dramatically and is still rapidly increasing, but the translation into practical guidelines with tailored advices will cost much effort in the near future...
  6. ncbi The role of xanthine oxidase in thiopurine metabolism: a case report
    Dennis R Wong
    Department of Clinical Pharmacy, Orbis Medical Center, Maasland Hospital, Sittard, The Netherlands
    Ther Drug Monit 29:845-8. 2007
    ..High XO activity led to an inability to form detectable levels of active thiopurine metabolites 6-TGN and 6-MMPR. This finding emphasizes the important role of XO in the biotransformation of thiopurines...
  7. pmc Serotonin transporter polymorphism and bleeding time during SSRI therapy
    Dahlia M C Hougardy
    Department of Clinical Pharmacy, Maxima Medical Center, Veldhoven, The Netherlands
    Br J Clin Pharmacol 65:761-6. 2008
    ....
  8. ncbi Promising treatment of autoimmune hepatitis with 6-thioguanine after adverse events on azathioprine
    Nanne K H de Boer
    Dept of Gastroenterology and Hepatology, VU University Medical Center, Amsterdam, The Netherlands
    Eur J Gastroenterol Hepatol 17:457-61. 2005
    ..All three patients improved clinically. Therapeutic drug monitoring was performed. The prospective evaluation of 6-thioguanine as a possible immunosuppressive drug in autoimmune hepatitis patients is warranted...
  9. ncbi 6-Thioguanine-related hepatotoxicity in patients with inflammatory bowel disease: dose or level dependent?
    Luc J J Derijks
    J Hepatol 44:821-2. 2006
  10. ncbi Some cases demonstrating the clinical usefulness of therapeutic drug monitoring in thiopurine-treated inflammatory bowel disease patients
    Lennard P L Gilissen
    Department of Gastroenterology, Maasland Hospital, Sittard, The Netherlands
    Eur J Gastroenterol Hepatol 16:705-10. 2004
    ..In addition, sophisticated 6-MP metabolite level-guided therapy, including non-compliance, is demonstrated. These cases demonstrate that TDM may improve effectivity and safety of thiopurine treatment...
  11. ncbi Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression
    Zuzana Zelinkova
    Laboratory of Experimental Internal Medicine, Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands
    Clin Gastroenterol Hepatol 4:44-9. 2006
    ..The aim of our study was to determine the relative contribution of ITPA and TPMT mutations to the development of toxicity induced by AZA treatment in IBD patients...
  12. ncbi Pharmacogenomics in inflammatory bowel disease
    Laurence J Egan
    Department of Pharmacology, National University of Ireland, Galway, Ireland
    Clin Gastroenterol Hepatol 4:21-8. 2006
    ..If this promise can be realized, pharmacogenomics will deliver the opportunity for personalized medicine...